miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 15, 2025

Vanguard Opens XRP ETF Access to 50 Million Clients: Could This Push XRP to $3 by January?

View original at finance.yahoo.com
Vanguard Opens XRP ETF Access to 50 Million Clients: Could This Push XRP to $3 by January? Volodymyr Maksymchuk / Shutterstock.com Quick Read Vanguard opened XRP ETF access to 50+ million clients on December 2, 2025, reversing years of avoiding crypto and adding institutional credibility to XRP investments…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • XRP ETF inflows hit $1 billion within four weeks, the fastest pace since Ethereum ETFs launched in July 2024

    80% confidence
  • XRP experienced 15 consecutive days of net inflows and zero outflows

    80% confidence
  • In standard timing scenario, XRP could see $20-30 million daily inflows and face resistance between $2.40 and $2.80, with $3 target shifting to Q1 or Q2 2026

    80% confidence
  • In fast adoption scenario, XRP price could clear $2.25, hold $2.60, then push toward $2.80 with potential $3 test by end of January 2026

    80% confidence
  • In downside scenario with macro volatility, XRP may drift between $1.95 and $2.30 through January, failing to close above $2.25

    80% confidence
  • Vanguard advisors operate on quarterly review cycles, meaning capital deployment spreads across weeks or months rather than concentrating in January

    80% confidence
  • XRP's run to $3 could be delayed until Q1 or Q2 2026 due to standard institutional timing

    80% confidence

Data points we hold from this source

XRP · exchange supply1.6 billion_tokens
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Vanguard Opens XRP ETF Access to 50 Million Clients: Could This Push XRP to $3 by January? — Source | Via News | es.VIA.NEWS